R&D channel feed

FDA slaps As­traZeneca's MCL-1 can­cer drug with a hold af­ter safe­ty is­sue — 2 years af­ter Am­gen axed a trou­bled ri­val

4 years ago
FDA+

Ra­dius rock­ets high­er as Kel­ly Mar­tin boasts of a big PhI­II suc­cess — but the spoils be­long to Menar­i­ni

4 years ago

Sur­geons suc­cess­ful­ly at­tach pig kid­ney to a hu­man for the first time, us­ing tech from Unit­ed's Re­vivi­cor

4 years ago
Discovery

No­vo CEO Lars Fruer­gaard Jør­gensen on R&D risk, the deal strat­e­gy and tar­gets for gen­der di­ver­si­ty

4 years ago

As­traZeneca's for­mer an­tibi­otics unit claims a PhI­II win in drug-re­sis­tant bac­te­ria af­fect­ing sick­ly pa­tients

4 years ago

Galera shares take a nose­dive in the wake of un­ex­pect­ed PhI­II flop

4 years ago

Take­da, Wave Life Sci­ences re­vise their $230M R&D col­lab­o­ra­tion, drop­ping dis­cov­ery work

4 years ago
Deals

Roche-Atea’s Covid-19 pill fails mid-stage tri­al, cloud­ing fu­ture for close­ly watched pro­gram

4 years ago
Coronavirus

Phath­om's old Take­da drug bests Pre­vacid in a PhI­II GI tri­al. Next stop? The FDA

4 years ago

Ver­tex gets much-need­ed win with ‘ex­tra­or­di­nary’ first pa­tient re­sults on po­ten­tial di­a­betes cure

4 years ago
Cell/Gene Tx

Small biotech says its Covid-19 vac­cine spurs more an­ti­bod­ies than As­traZeneca’s. Will sup­ply deals come now?

4 years ago
Coronavirus

Bio­gen hit by ALS set­back with PhI­II fail­ure for tofersen — but fol­lows a fa­mil­iar strat­e­gy high­light­ing the pos­i­tive

4 years ago

A Bob Nelsen start­up turns to Har­vard to help sharp­en its tech, in­spir­ing first spin­out

4 years ago
Deals
Manufacturing

No­var­tis de­vel­op­ment chief John Tsai: 'We go deep in the new plat­form­s'

4 years ago

Imfinzi/treme­li­mum­ab com­bo scores As­traZeneca an­oth­er OS win — this time in liv­er can­cer

4 years ago

As Mod­er­na's search for African man­u­fac­tur­ing site ramps up, Ban­cel an­swers crit­i­cism about do­na­tions

4 years ago
Manufacturing

As flu sea­son emerges, BD com­pletes sy­ringe man­u­fac­tur­ing lines with help from US gov­ern­ment; Hot off sum­mer­time de­but on NYSE, con­struc­tion on Ste­vana­to's mid­west site be­gins

4 years ago
Manufacturing

As­traZeneca on­col­o­gy R&D chief Su­san Gal­braith: 'Y­ou're go­ing to need or­thog­o­nal com­bi­na­tion­s'

4 years ago

FDA+ roundup: Marks on Wood­cock­'s tenure as act­ing com­mis­sion­er; FDA lead­ers of­fer per­spec­tive on bar­ri­ers to di­ver­si­ty in re­search

4 years ago

CRISPR Ther­a­peu­tics claims safe­ty ad­van­tage in first big look at off-the-shelf CAR-T da­ta, but dura­bil­i­ty in ques­tion

4 years ago
Cell/Gene Tx

Cure­Vac spins a ma­jor set­back on their mR­NA Covid vac­cine in­to an ad­van­tage in the mar­ket wars to come

4 years ago
Coronavirus

Sci­en­tist be­hind Mer­ck­'s Covid pill: We need to watch out for re­sis­tance

4 years ago
Coronavirus

C4 co-founder re­signs as Dana-Far­ber trustee in the wake of new con­flict of in­ter­est poli­cies — re­port

4 years ago

Idor­si­a's Fab­ry dis­ease pro­gram flops a PhI­II study, leav­ing its fu­ture un­clear

4 years ago
First page Previous page 156157158159160161162 Next page Last page
A service from the Financial Times